Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular
Cambium Bio (ASX:CMB) has flagged approval from the U.S. FDA for phase…
Cambium Bio Limited (ASX:CMB)
About Cambium Bio Limited
Key Information
CMB In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 11/07/2025 | Cambium Bio Clears FDA Regulatory Hurdles | 108.46KB | 745 |
| 30/06/2025 | Cambium Bio Receives Ethics Approvals | 135.38KB | 207 |
| 23/05/2025 | Change of Address | 83.46KB | 217 |
| 22/05/2025 | Initial Director's Interest Notice - Denese Marks | 183.14KB | 215 |
| 22/05/2025 | Final Director's Interest Notice - Barry Sechos | 183.54KB | 203 |
| 21/05/2025 | Board and Company Secretary Changes | 146.97KB | 231 |
| 28/04/2025 | Price Sensitive PS Quarterly Activities/Appendix 4C Cash Flow Report | 259.75KB | 1.1K |
| 14/04/2025 | Change of registry address | 64.39KB | 241 |